{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:32:58Z","timestamp":1794666778333,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02148-3","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:51:59Z","timestamp":1759827119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4495-7464","authenticated-orcid":false,"given":"Julien","family":"Ognard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevda","family":"Alipour Khabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherief","family":"Ghozy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"El Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Kallmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramanathan","family":"Kadirvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Kallmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Brinjikji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2148_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/bmb\/ldaa034","volume":"136","author":"SP Mollan","year":"2020","unstructured":"Mollan SP, Grech O, Alimajstorovic Z et al (2020) New horizons for idiopathic intracranial hypertension: advances and challenges. Br Med Bull 136:118\u2013126. https:\/\/doi.org\/10.1093\/bmb\/ldaa034","journal-title":"Br Med Bull"},{"key":"2148_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1212\/cont.0000000000001586","volume":"31","author":"JJ Chen","year":"2025","unstructured":"Chen JJ, Mollan SP (2025) Treatment and monitoring of idiopathic intracranial hypertension. Continuum Lifelong Learn Neurol 31:728\u2013756. https:\/\/doi.org\/10.1212\/cont.0000000000001586","journal-title":"Continuum Lifelong Learn Neurol"},{"key":"2148_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2017.01.006","volume":"124","author":"KP Kilgore","year":"2017","unstructured":"Kilgore KP, Lee MS, Leavitt JA et al (2017) Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity. Ophthalmology 124:697\u2013700. https:\/\/doi.org\/10.1016\/j.ophtha.2017.01.006","journal-title":"Ophthalmology"},{"key":"2148_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1212\/CON.0000000000001570","volume":"31","author":"AA Antonio","year":"2025","unstructured":"Antonio AA (2025) Clinical features and diagnosis of idiopathic intracranial hypertension. Continuum (Minneap Minn) 31:709\u2013727. https:\/\/doi.org\/10.1212\/CON.0000000000001570","journal-title":"Continuum (Minneap Minn)"},{"key":"2148_CR5","doi-asserted-by":"publisher","first-page":"e2138","DOI":"10.1212\/WNL.0000000000207866","volume":"101","author":"S Abbott","year":"2023","unstructured":"Abbott S, Chan F, Tahrani AA et al (2023) Weight management interventions for adults with idiopathic intracranial hypertension. Neurology 101:e2138\u2013e2150. https:\/\/doi.org\/10.1212\/WNL.0000000000207866","journal-title":"Neurology"},{"key":"2148_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/medicina61030450","volume":"61","author":"A Almaqhawi","year":"2025","unstructured":"Almaqhawi A, Alokley A, Alamri R et al (2025) Effectiveness of topiramate versus Acetazolamide in the management of idiopathic intracranial hypertension: asystematic review and Meta-Analysis. Med (Kaunas) 61:450. https:\/\/doi.org\/10.3390\/medicina61030450","journal-title":"Med (Kaunas)"},{"key":"2148_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035545","volume":"102","author":"A Goyal","year":"2023","unstructured":"Goyal A, Zarroli K (2023) Should topiramate be initial therapy in the management of idiopathic intracranial hypertension? A literature review. Medicine (Baltimore) 102:e35545. https:\/\/doi.org\/10.1097\/MD.0000000000035545","journal-title":"Medicine (Baltimore)"},{"key":"2148_CR8","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8942","author":"J Ognard","year":"2025","unstructured":"Ognard J, Douri D, El Hajj G et al (2025) Future is Ven(o)us: A 5-year narrative update on the venous route for therapeutics in neurointervention. AJNR Am J Neuroradiol. https:\/\/doi.org\/10.3174\/ajnr.A8942. ajnr.A8942","journal-title":"AJNR Am J Neuroradiol"},{"key":"2148_CR9","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/jnnp-2017-317440","volume":"89","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Davies B, Silver NC et al (2018) Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry 89:1088\u20131100. https:\/\/doi.org\/10.1136\/jnnp-2017-317440","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2148_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4239\/wjd.v6.i6.807","volume":"6","author":"EM Candeias","year":"2015","unstructured":"Candeias EM (2015) Gut-brain connection: the neuroprotective effects of the anti-diabetic drug liraglutide. WJD 6:807. https:\/\/doi.org\/10.4239\/wjd.v6.i6.807","journal-title":"WJD"},{"key":"2148_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/379069a0","volume":"379","author":"MD Turton","year":"1996","unstructured":"Turton MD, O\u2019Shea D, Gunn I et al (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69\u201372. https:\/\/doi.org\/10.1038\/379069a0","journal-title":"Nature"},{"key":"2148_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0972","volume":"9","author":"HF Botfield","year":"2017","unstructured":"Botfield HF, Uldall MS, Westgate CSJ et al (2017) A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med 9:eaan0972. https:\/\/doi.org\/10.1126\/scitranslmed.aan0972","journal-title":"Sci Transl Med"},{"key":"2148_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12987-022-00335-x","volume":"19","author":"SN Andreassen","year":"2022","unstructured":"Andreassen SN, Toft-Bertelsen TL, Wardman JH et al (2022) Transcriptional profiling of transport mechanisms and regulatory pathways in rat choroid plexus. Fluids Barriers CNS 19:44. https:\/\/doi.org\/10.1186\/s12987-022-00335-x","journal-title":"Fluids Barriers CNS"},{"key":"2148_CR14","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/brain\/awad003","volume":"146","author":"JL Mitchell","year":"2023","unstructured":"Mitchell JL, Lyons HS, Walker JK et al (2023) The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain 146:1821\u20131830. https:\/\/doi.org\/10.1093\/brain\/awad003","journal-title":"Brain"},{"key":"2148_CR15","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. https:\/\/doi.org\/10.1136\/bmj.n71. BMJ n71","DOI":"10.1136\/bmj.n71"},{"key":"2148_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","volume":"81","author":"DI Friedman","year":"2013","unstructured":"Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81:1159\u20131165. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a55f17","journal-title":"Neurology"},{"key":"2148_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"2148_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"2148_CR19","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"2148_CR20","unstructured":"Risk of bias tools - ROBINS-I V2 tool https:\/\/www.riskofbias.info\/welcome\/robins-i-v2. Accessed 16 Aug 2025"},{"key":"2148_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jclinepi.2023.05.010","volume":"159","author":"HJ Sch\u00fcnemann","year":"2023","unstructured":"Sch\u00fcnemann HJ, Brennan S, Akl EA et al (2023) The development methods of official GRADE articles and requirements for claiming the use of GRADE - a statement by the GRADE guidance group. J Clin Epidemiol 159:79\u201384. https:\/\/doi.org\/10.1016\/j.jclinepi.2023.05.010","journal-title":"J Clin Epidemiol"},{"key":"2148_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"2148_CR23","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1212\/CPJ.0000000000001063","volume":"11","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Tahrani AA, Sinclair AJ (2021) The potentially modifiable risk factor in idiopathic intracranial hypertension: body weight. Neurol Clin Pract 11:e504\u2013e507. https:\/\/doi.org\/10.1212\/CPJ.0000000000001063","journal-title":"Neurol Clin Pract"},{"key":"2148_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01821-3","author":"W Halloum","year":"2024","unstructured":"Halloum W, Dughem YA, Beier D, Pellesi L (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-024-01821-3","journal-title":"J Headache Pain"},{"key":"2148_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108271","volume":"33","author":"JK Sterling","year":"2020","unstructured":"Sterling JK, Adetunji MO, Guttha S et al (2020) GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep 33:108271. https:\/\/doi.org\/10.1016\/j.celrep.2020.108271","journal-title":"Cell Rep"},{"key":"2148_CR26","doi-asserted-by":"publisher","unstructured":"(2023) Oral presentations. Euro J Neurol 30:43\u2013119. https:\/\/doi.org\/10.1111\/ene.15948","DOI":"10.1111\/ene.15948"},{"key":"2148_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01631-z","author":"N Krajnc","year":"2023","unstructured":"Krajnc N, Itariu B, Macher S et al (2023) Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-023-01631-z","journal-title":"J Headache Pain"},{"key":"2148_CR28","doi-asserted-by":"publisher","unstructured":"Azzam AY, Essibayi MA, Farkas N et al\u00a0(2024) Efficacy of Tirzepatide dual GIP\/GLP-1 receptor agonist in patients with idiopathic intracranial hypertension. A Real-World Propensity Score-Matched Study. medRxiv. https:\/\/doi.org\/10.1101\/2024.11.12.24317193.","DOI":"10.1101\/2024.11.12.24317193"},{"key":"2148_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70019","author":"AY Azzam","year":"2025","unstructured":"Azzam AY, Essibayi MA, Farkas N et al (2025) Efficacy of tirzepatide dual GIP\/GLP-1 receptor agonist in patients with idiopathic intracranial hypertension. A real\u2010world propensity score\u2010matched study. Endocrinology, Diabetes & Metabolism. https:\/\/doi.org\/10.1002\/edm2.70019","journal-title":"Endocrinology, Diabetes & Metabolism"},{"key":"2148_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12987-025-00652-x","volume":"22","author":"MN Jensen","year":"2025","unstructured":"Jensen MN, Israelsen IME, Wardman JH et al (2025) Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats. Fluids Barriers CNS 22:41. https:\/\/doi.org\/10.1186\/s12987-025-00652-x","journal-title":"Fluids Barriers CNS"},{"key":"2148_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11916-024-01215-9","volume":"28","author":"B Heckel","year":"2024","unstructured":"Heckel B (2024) Idiopathic intracranial hypertension after abrupt cessation of medication: A case report of abrupt Glucagon-like peptide-1 (GLP-1) receptor agonist cessation and review of the literature. Curr Pain Headache Rep 28:453\u2013456. https:\/\/doi.org\/10.1007\/s11916-024-01215-9","journal-title":"Curr Pain Headache Rep"},{"key":"2148_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/dom.13111","volume":"19","author":"I Idris","year":"2017","unstructured":"Idris I (2017) News and views. Diabetes Obes Metab 19:1640\u20131642. https:\/\/doi.org\/10.1111\/dom.13111","journal-title":"Diabetes Obes Metab"},{"key":"2148_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad272","author":"Z Alimajstorovic","year":"2023","unstructured":"Alimajstorovic Z, Mitchell JL, Yiangou A et al (2023) Determining the role of novel metabolic pathways in driving intracranial pressure reduction after weight loss. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcad272","journal-title":"Brain Commun"},{"key":"2148_CR34","doi-asserted-by":"publisher","unstructured":"Azzam AY, Essibayi MA, Vaishnav D et al\u00a0(2024) Semaglutide as an adjunctive therapy to standard management for idiopathic intracranial hypertension. A Real-World Data-Based Retrospective Analysis. medRxiv. https:\/\/doi.org\/10.1101\/2024.11.12.24317197.","DOI":"10.1101\/2024.11.12.24317197"},{"key":"2148_CR35","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41433-023-02908-y","volume":"38","author":"O Grech","year":"2024","unstructured":"Grech O, Mitchell JL, Lyons HS et al (2024) Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in idiopathic intracranial hypertension. Eye 38:1374\u20131379. https:\/\/doi.org\/10.1038\/s41433-023-02908-y","journal-title":"Eye"},{"key":"2148_CR36","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/acn3.52300","volume":"12","author":"AY Azzam","year":"2025","unstructured":"Azzam AY, Essibayi MA, Vaishnav D et al (2025) Liraglutide for idiopathic intracranial hypertension: a real-world propensity score\u2010matched study. Ann Clin Transl Neurol 12:746\u2013755. https:\/\/doi.org\/10.1002\/acn3.52300","journal-title":"Ann Clin Transl Neurol"},{"key":"2148_CR37","doi-asserted-by":"publisher","unstructured":"O\u2019Leary S, Price A, Camarillo-Rodriguez L et al\u00a0(2025) Impact of GLP-1 receptor agonists on idiopathic intracranial hypertension clinical and neurosurgical outcomes: a propensity-matched multi-institutional cohort study. J Neurosurg. 1\u201311. https:\/\/doi.org\/10.3171\/2025.1.jns242357.","DOI":"10.3171\/2025.1.jns242357"},{"key":"2148_CR38","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/s41433-025-03807-0","volume":"39","author":"L Kravetz","year":"2025","unstructured":"Kravetz L, Leeman S, Regev T et al (2025) The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic intracranial hypertension patients: a retrospective study. Eye 39:2090\u20132095. https:\/\/doi.org\/10.1038\/s41433-025-03807-0","journal-title":"Eye"},{"key":"2148_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.2020","author":"GS Sioutas","year":"2025","unstructured":"Sioutas GS, Mualem W, Reavey-Cantwell J, Rivet DJ (2025) GLP-1 receptor agonists in idiopathic intracranial hypertension. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2020","journal-title":"JAMA Neurol"},{"key":"2148_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D et al (2023) A global federated real-world data and analytics platform for research. JAMIA Open. https:\/\/doi.org\/10.1093\/jamiaopen\/ooad035","journal-title":"JAMIA Open"},{"issue":"25","key":"2148_CR41","doi-asserted-by":"publisher","first-page":"00589","DOI":"10.1016\/j.neurol.2025.08.002","volume":"S0035\u20133787","author":"J Ognard","year":"2025","unstructured":"Ognard J, El Hajj G, Ghozy S et al (2025) Quality of life in patients with spontaneous intracranial hypotension: A systematic review and meta-analysis. Rev Neurol (Paris). S0035\u20133787(25):00589\u20132. https:\/\/doi.org\/10.1016\/j.neurol.2025.08.002","journal-title":"Rev Neurol (Paris)."},{"key":"2148_CR42","unstructured":"IIH-Advance In: University of Birmingham. https:\/\/www.birmingham.ac.uk\/research\/metabolism-systems\/translational-brain-science\/iih-advance.aspx. Accessed 16 Aug 2025"},{"key":"2148_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamaneurol.2021.0659","volume":"78","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Mitchell JL, Ottridge RS et al (2021) Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension. JAMA Neurol 78:678\u2013686. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0659","journal-title":"JAMA Neurol"},{"key":"2148_CR44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00701-019-03868-7","volume":"161","author":"PRAM Depauw","year":"2019","unstructured":"Depauw PRAM, Groen RJM, Van Loon J et al (2019) The significance of intra-abdominal pressure in neurosurgery and neurological diseases: a narrative review and a conceptual proposal. Acta Neurochir (Wien) 161:855\u2013864. https:\/\/doi.org\/10.1007\/s00701-019-03868-7","journal-title":"Acta Neurochir (Wien)"},{"key":"2148_CR45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/neuros\/nyx186","volume":"82","author":"DMS Raper","year":"2018","unstructured":"Raper DMS, Ding D, Buell TJ et al (2018) Effect of body mass index on venous sinus pressures in idiopathic intracranial hypertension patients before and after endovascular stenting. Neurosurgery 82:555\u2013561. https:\/\/doi.org\/10.1093\/neuros\/nyx186","journal-title":"Neurosurgery"},{"key":"2148_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.37349\/eds.2023.00015","volume":"1","author":"S Sheth","year":"2023","unstructured":"Sheth S, Patel A, Foreman M et al (2023) The protective role of GLP-1 in neuro-ophthalmology. Explor Drug Sci 1:221\u2013238. https:\/\/doi.org\/10.37349\/eds.2023.00015","journal-title":"Explor Drug Sci"},{"key":"2148_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ncl.2016.08.004","volume":"35","author":"M Wall","year":"2017","unstructured":"Wall M (2017) Update on idiopathic intracranial hypertension. Neurol Clin 35:45\u201357. https:\/\/doi.org\/10.1016\/j.ncl.2016.08.004","journal-title":"Neurol Clin"},{"key":"2148_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11910-024-01347-w","volume":"24","author":"PS Subramanian","year":"2024","unstructured":"Subramanian PS (2024) Novel approaches to the treatment of idiopathic intracranial hypertension. Curr Neurol Neurosci Rep 24:265\u2013272. https:\/\/doi.org\/10.1007\/s11910-024-01347-w","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2148_CR49","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jocn.2021.11.029","volume":"95","author":"MTM Wang","year":"2022","unstructured":"Wang MTM, Bhatti MT, Danesh-Meyer HV (2022) Idiopathic intracranial hypertension: pathophysiology, diagnosis and management. J Clin Neurosci 95:172\u2013179. https:\/\/doi.org\/10.1016\/j.jocn.2021.11.029","journal-title":"J Clin Neurosci"},{"key":"2148_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14737167.2021.1860022","volume":"21","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Yang L, Shi H et al (2021) The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 diabetes: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res 21:221\u2013233. https:\/\/doi.org\/10.1080\/14737167.2021.1860022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2148_CR51","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1001\/jamaneurol.2019.1812","volume":"76","author":"NJ Adderley","year":"2019","unstructured":"Adderley NJ, Subramanian A, Nirantharakumar K et al (2019) Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol 76:1088\u20131098. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1812","journal-title":"JAMA Neurol"},{"key":"2148_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12933-025-02840-3","volume":"24","author":"ASP Tang","year":"2025","unstructured":"Tang ASP, Hsu JTY, Chong SKS et al (2025) Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety. Cardiovasc Diabetol 24:285. https:\/\/doi.org\/10.1186\/s12933-025-02840-3","journal-title":"Cardiovasc Diabetol"},{"key":"2148_CR53","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00415-021-10700-9","volume":"269","author":"A Yiangou","year":"2022","unstructured":"Yiangou A, Mitchell JL, Nicholls M et al (2022) Obstructive sleep Apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT). J Neurol 269:1945\u20131956. https:\/\/doi.org\/10.1007\/s00415-021-10700-9","journal-title":"J Neurol"},{"key":"2148_CR54","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I et al (2024) Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med 391:1193\u20131205. https:\/\/doi.org\/10.1056\/NEJMoa2404881","journal-title":"N Engl J Med"},{"key":"2148_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-025-00995-3","author":"D Bellavance","year":"2025","unstructured":"Bellavance D, Chua S, Mashimo H (2025) Gastrointestinal motility effects of GLP-1 receptor agonists. Curr Gastroenterol Rep. https:\/\/doi.org\/10.1007\/s11894-025-00995-3","journal-title":"Curr Gastroenterol Rep"},{"key":"2148_CR56","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.001045","volume":"77","author":"M Kokkorakis","year":"2025","unstructured":"Kokkorakis M, Chakhtoura M, Rhayem C et al (2025) Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev 77:100002. https:\/\/doi.org\/10.1124\/pharmrev.123.001045","journal-title":"Pharmacol Rev"},{"key":"2148_CR57","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1042\/cs20210040","volume":"135","author":"CT Supuran","year":"2021","unstructured":"Supuran CT (2021) Emerging role of carbonic anhydrase inhibitors. Clin Sci 135:1233\u20131249. https:\/\/doi.org\/10.1042\/cs20210040","journal-title":"Clin Sci"},{"key":"2148_CR58","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.2019","author":"NJ Newman","year":"2025","unstructured":"Newman NJ, Bruce BB, Biousse V (2025) GLP-1 RAs for idiopathic intracranial hypertension\u2014time for a trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2019","journal-title":"JAMA Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02148-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02148-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02148-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T21:03:49Z","timestamp":1759871029000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02148-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2148"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02148-3","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.O. received research grants from the French Society of Neuroradiology SFNR, the French network of University Hospitals HUGO (\u2018H\u00f4pitaux Universitaires du Grand Ouest\u2019), INNOVEO-Chu De Brest, Medtronic, Phenox, Institut Servier, Philippe Foundation, Philips, and receives consulting fees from Balt; S.A.K. reports no disclosures relevant to the manuscript; S.G. reports no disclosures relevant to the manuscript; G.E.H. reports no disclosures relevant to the manuscript; K.M.K. is CEO and holds equity in Nested Knowledge, Inc., hold equity in and serves as Director of Superior Medical Experts, hold equity in and serves as Director of Piraeus Medical, Inc., and served as an advisor to Nuvox Pharma LLC; R.K. received research support from Cerenovus Inc, Medtronic, Endovascular Engineering, Frontier Bio, Sensome Inc, Endomimetics, Ancure LLC, Neurogami Medical, MIVI Biosciences, Monarch Biosciences, Stryker, Conway Medical, Piraeus Medical, Rion Inc, and Bionaut Labs. He holds research grants from NIH and NSF; J.J.C. reports no disclosures relevant to the manuscript; D.F.K. holds equity in Nested Knowledge, Superior Medical Editors, and Conway Medical, Marblehead Medical and Piraeus Medical. He receives grant support from MicroVention, Medtronic, Balt, and Insera Therapeutics; has served on the Data Safety Monitoring Board for Vesalio; and received royalties from Medtronic; W.B. holds equity in Nested Knowledge, Superior Medical Editors, Piraeus Medical, Sonoris Medical, and MIVI Neurovascular. He receives royalties from Medtronic and Balloon Guide Catheter Technology. He receives consulting fees from Medtronic, Stryker, Imperative Care, Microvention, MIVI Neurovascular, Cerenovus, Asahi, and Balt. He serves in a leadership or fiduciary role for MIVI Neurovascular, Marblehead Medical LLC, Interventional Neuroradiology (Editor in Chief), Piraeus Medical, and WFITN.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}